Search results
Results from the WOW.Com Content Network
Intercept said only one case of liver transplant was possibly related to the drug. The company, which holds the drug's U.S. commercial rights, was acquired by Italy's Alfasigma for nearly $800 ...
The rejection marks Intercept's second failed attempt at securing approval for the drug to treat patients with non-alcoholic steatohepatitis (NASH) - a liver disease that affects 5% of U.S. adults ...
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) completed the sale of its international business for $405 million in upfront consideration. The company held a pre-submission meeting with FDA in July ...
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary ...
RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ: ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA ...
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced additional positive data from its pivotal Phase 3 REGENERATE trial Wednesday. The trial is evaluating Intercept's obeticholic acid, or OCA ...
For premium support please call: 800-290-4726 more ways to reach us
Intercept said its treatment led to statistically significant reduction in fibrosis in patients with NASH after 18 months compared to the placebo, based on interim analysis. "Overall, we expect ...